Manufacturing roundup: Actylis opens the doors to a facility in Oregon; Emergent reports Q4 numbers
The ingredients manufacturer Actylis has opened a new 30,000-square-foot facility in the city of Eugene, OR.
Actylis CEO Gilles Cottier said in a statement the new site will allow the company to manufacture APIs and intermediates for clinical trials — and on a commercial scale.
“We designed this facility specifically to enable us to develop and produce innovative APIs for our customers. Our intimate knowledge of their needs, our consultative approach, and our focus on innovation offer unparalleled choice and flexibility,” Cottier added.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters